Radar · Ophthalmology in California
Best Ophthalmology Companies in California, United States
The 170 best Ophthalmology companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kriya Therapeutics.
By Riya SenguptaFinancials
170companies tracked
$5.4Bdisclosed funding
1unicorns
100have raised
Ranked: Best Ophthalmology companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | Shankar Ramaswamy Co-Founder & CEO | WordPress Site EditorWordPressMySQL+12 | — | — |
| 2 | Science 🦄 Provider of online science magazine 72Funding top 13%Patents top 20%Moat top 24%Innovation top 33% All 9 signals ▾Fundingtop 13% Patentstop 20% Moattop 24% Innovationtop 33% Growthtop 35% Markettop 38% Globaltop 42% Talentbottom 49% Techbottom 46% Funding: Raised $360M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Patents: 245 patents matched (strict assignee match) · 102 filings since 2022 vs 115 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $360M | 3 mo ago | 76 | Max Hodak Founder & CEO | Apple iCloud MailGoogle WorkspaceRuby+12 | 245 patents Specialty surfactants and polyether polymer derivatives for cosmetics and advanced chemical synthesis | 3 job openings · 1 award |
| 3 | AcuFocus Developer of small aperture technology-based ophthalmic devices | $219M | 93 mo ago | 27 | Alan Waterhouse CEO | — | 199 patents Intraocular lens design, molding, masking, and adjustable optics for vision correction | — |
| 4 | Unity Biotechnology Developer of therapeutics solutions for numerous diseases of aging | $206M | 70 mo ago | 32 | Jan Van Deursen Cofounder | DrupalPHPAmazon Web Services+20 | 244 patents Senolytic drugs and Tie‑2/VEGF antibodies for treating ocular vascular diseases | — |
| 5 | Tenvie Developer of small molecule therapies for neurological, cardiometabolic, and ophthalmic diseases | $200M | 17 mo ago | — | Brian Cuneo Co-Founder & CLO | — | — | 4 job openings |
| 6 | RxSight Developer of adjustable intraocular lens technology | $194M | 66 mo ago | 263 263 → 417 (+59%) | — | WordPressMySQLPHP+35 | 145 patents Adjustable intraocular lenses using UV‑controlled polymerization and diffractive optics | — |
| 7 | 4D Molecular Therapeutics Developer of gene therapeutics for genetic disorders | $187M | 72 mo ago | 147 147 → 216 (+47%) | David Kirn Md Co-Founder & CEO | WordPressBugHerdMySQL+23 | 246 patents Patents concentrated in chemistry & materials | — |
| 8 | Ivantis Innovative microstent solutions for glaucoma management and surgical eye care | $166M | 112 mo ago | 132 | — | — | 149 patents Patents concentrated in health & consumer products | — |
| 9 | LENZ Therapeutics Developer of ophthalmic pharmaceutical products | $133M | 39 mo ago | 20 | Gerald Horn Founder | WordPressApple iCloud MailMicrosoft 365+23 | — | 1 job opening |
| 10 | Ashvattha Therapeutics Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases 45Funding top 23%Moat top 36%Talent top 38%Market bottom 41% All 6 signals ▾Fundingtop 23% Moattop 36% Talenttop 38% Marketbottom 41% Globalbottom 37% Newsbottom 22% Funding: Raised $130M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $130M | 17 mo ago | 40 | Kannan Rangaramanujam Co-Founder & CTO | — | — | — |
| 11 | Sight Sciences Developer of surgical systems for the treatment of ophthalmological diseases | $129M | 66 mo ago | 204 204 → 233 (+14%) | — | WordPressMySQLPHP+31 | 219 patents Ocular drug delivery devices and intraocular implant technologies for eye treatment | — |
| 12 | Transcend Medical Glaucoma intervention devices | $122M | 137 mo ago | 20 | — | — | — | — |
| 13 | Glaukos Developer of implants to treat glaucoma | $118M | 72 mo ago | 907 907 → 1,093 (+21%) | — | WordPressMySQLPHP+24 | 485 patents Bioresorbable ocular drug‑delivery implants and glaucoma stents for controlled eye therapy | — |
| 14 | PowerVision implantable intraocular lenses | $109M | 118 mo ago | 59 | — | — | 210 patents Design and delivery of accommodating intraocular lenses for eye surgery | — |
| 15 | Ray Therapeutics Developer of therapeutics for degenerative retinal diseases 48Funding top 19%Growth top 35%Tech top 40%Moat top 42% All 7 signals ▾Fundingtop 19% Growthtop 35% Techtop 40% Moattop 42% Talentbottom 49% Globalbottom 39% Marketbottom 28% Funding: Raised $106M across 6 rounds · 6 rounds over 4 yrs (1.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $106M | 1 mo ago | 10 | Paul Bresge Co-Founder & CEO | WordPressMySQLMariaDB+21 | — | — |
| 16 | Iconic Therapeutics Immunoconjugate proteins that trigger the immune system to destroy invader cells to treat AMD and ocular… | $105M | 85 mo ago | 4 | Kirk Dornbush Co-Founder | — | — | — |
| 17 | OptiMedica Developer of medical devices to treat ocular diseases | $95M | 163 mo ago | 60 | Paweł Nessel CEO | — | 600 patents Laser ophthalmic surgery devices and patient interface technologies. | — |
| 18 | Lineage Cell Therapeutics Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders | $94M | 25 mo ago | 75 | Brian Culley CEO | WordPressMySQLPHP+18 | — | — |
| 19 | WaveTec Vision Intraoperative guidance system for Intraocular lens alignment during cataract surgery | $91M | 147 mo ago | 64 | Tom Frinzi President | — | 89 patents Intraocular lens power estimation and surgical wavefront measurement technologies. | — |
| 20 | AqueSys Gelatin stent to treat glaucoma | $88M | 149 mo ago | 20 | — | — | 303 patents Ophthalmic surgical devices for intraocular shunt implantation to treat glaucoma | — |
| 21 | Eyconis Developer of ophthalmology therapeutics for diseases like AMD, DME, RVO, and GA | $85M | 8 mo ago | — | Emmett Cunningham Co-Founder & Executive Chairman of the Board | WebflowApple iCloud MailMicrosoft 365+11 | — | 1 job opening |
| 22 | Spotlight Therapeutics Developer of cancer therapeutics using gene editing | $81M | 32 mo ago | 32 | — | — | — | — |
| 23 | Perceive Bio Developer of therapeutics to treat diabetes and eye diseases | $78M | 41 mo ago | 12 | Anne Rubin President | — | — | — |
| 24 | Trefoil Therapeutics Developer protein engineering drugs to treat corneal endothelial diseases | $73M | 13 mo ago | 10 | Michael Blaber Co-Founder | — | — | — |
| 25 | Retrotope Developer of therapeutics to treat neurodegenerative and ophthalmological diseases | $70M | 65 mo ago | 21 | Mikhail Shchepinov Founder | — | 221 patents Deuterated polyunsaturated fatty acid therapeutics for neurodegenerative disease treatment | — |
| 26 | Epicrispr Bio Developer of therapeutics for multiple disease 35Funding top 23%Talent top 38%Moat top 42%Tech bottom 43% All 6 signals ▾Fundingtop 23% Talenttop 38% Moattop 42% Techbottom 43% Globalbottom 37% Marketbottom 32% Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $68M | 14 mo ago | — | Lei Qi Founder | WordPressMySQLPHP+21 | — | — |
| 27 | Atia Vision Developer of a presbyopia correcting intraocular lens | $67M | 46 mo ago | 27 | Claudio Argento Co-Founder & CTO | — | — | — |
| 28 | Adverum Biotechnologies Developer of gene therapy based therapies for wet age-related macular degeneration & ophthalmologic disorders | $61M | 28 mo ago | 123 123 → 138 (+12%) | — | WordPressApple iCloud MailMicrosoft 365+21 | 319 patents Gene‑therapy AAV vectors for treating ocular neovascular and inflammatory eye diseases | — |
| 29 | Sydnexis Developer of a therapeutic formulation for treating myopia | $51M | 14 mo ago | — | Jacqueline Johnson Co-Founder & COO | WordPressMySQLPHP+18 | 119 patents Deuterated muscarinic antagonist ophthalmic formulations for pupil dilation and presbyopia treatment. | 1 launch |
| 30 | Nexis Vision Domain services, website hosting, and nameserver management for online success | $51M | 104 mo ago | — | Bernie Haffey President & CEO | — | — | — |
| 31 | Kalaris Therapeutics Developer of therapeutics for retinal disorders | $50M | 6 mo ago | — | Srinivas Akkaraju Co-Founder & Director | — | — | — |
| 32 | SynergEyes Hybrid contact lense manufacturers | $48M | 90 mo ago | 99 | — | WordPressBugHerdMySQL+21 | 38 patents Hybrid ophthalmic contact lenses combining optical correction with drug delivery | — |
| 33 | AiVita Biomedical Developer of dendritic cell immunotherapy for cancer and markets stem cells based facial serum for skin care | $46M | 65 mo ago | 20 20 → 21 (+5%) | — | — | 65 patents Cell membrane-bound signaling factor therapeutics for cancer immunotherapy | — |
| 34 | ViaLase Developer of image-guided devices for glaucoma treatments | $45M | 26 mo ago | 27 | — | WordPressMySQLPHP+16 | 134 patents Ophthalmic laser surgical devices for precise intraocular access and pressure reduction. | — |
| 35 | Stroma Medical Corp Permanent eye color change technology using lasers for natural results | $43M | 36 mo ago | 12 | Doug Daniels CEO | WordPressApple iCloud MailGoogle Workspace+14 | — | — |
| 36 | Myra Vision Developer of a medical device for the treatment of glaucoma | $42M | 35 mo ago | 25 | Robert Chang CEO | — | — | — |
| 37 | Phanes Therapeutics Developer of therapeutic solutions for treating immuno-oncology and eye disease | $40M | 60 mo ago | 28 | Ming Wang President and CEO | WordPressMySQLPHP+19 | 205 patents Therapeutic antibodies targeting immune checkpoints and tumor-associated antigens | — |
| 38 | Valitor Developer of therapeutic proteins for multiple disease conditions | $38M | 44 mo ago | 4 | — | — | 47 patents Multivalent peptide/protein–hyaluronic acid conjugate therapeutics for cancer and ocular disease | — |
| 39 | Second Sight Provider of an implantable visual prosthetic for blind individuals | $37M | 47 mo ago | 14 | Adam Mendelsohn CEO | — | 802 patents AI-driven cyber risk analytics and implantable brain-computer interface neurotechnology solutions. | — |
| 40 | LensGen Developer of Intraocular lens for presbyopia correction | $36M | 69 mo ago | 29 | Ramgopal Rao Founder & CEO | — | 86 patents Accommodating intraocular lens devices and fluidic silicone polymer lens components | — |
| 41 | CXL Ophthalmics Developer of a minimally-invasive treatment for corneal diseases | $32M | 44 mo ago | 7 | Michael Webb CEO | — | 47 patents Patents concentrated in health & consumer products | — |
| 42 | Character Biosciences Developer of therapeutics for the treatment of age-related eye diseases | $18M | 9 mo ago | 30 | Marcel Brug Co-Founder | — | — | — |
| 43 | Iolyx Therapeutics Developer of therapeutics for autoimmunity and ophthalmological conditions | $15M | 6 mo ago | — | Elizabeth Jeffords CEO & President | — | — | — |
| 44 | Combangio Developer of biotherapeutics to treat vision-threatening diseases | $15M | 37 mo ago | 3 | — | — | 57 patents Lyophilized mesenchymal stem cell secretome therapeutics and cellular fibronectin biomaterials | — |
| 45 | Visgenx Developer of gene therapy for age related muscular degeneration | $9M | 36 mo ago | 9 | Marty Emanuele Co-Founder & CSO | — | 16 patents ELOVL2-based gene therapy vectors for treating ocular diseases | — |
| 46 | MCAL Therapeutics Developer of treatments for ophthalmic diseases | $6M | 27 mo ago | 2 | — | — | — | — |
| 47 | Bio Usawa Developer of immunotherapy for cancer treatment | $3M | 7 mo ago | — | Richard Chin Co-Founder | BootstrapSlickjQuery+9 | — | — |
| 48 | AesculaTech AesculaTech is a biomedical startup that uses custom chemistry and smart materials to develop adaptable and… | $2M | 14 mo ago | 2 | Niki Bayat Co-Founder & CEO | — | 14 patents Advanced polymer-based drug delivery systems and injectable biomedical devices | — |
| 49 | Ocular Science Developer of post-operative drop care solutions | $175K | 5 mo ago | 12 | Anthony Sampietro CEO | — | — | — |
Top 12 Ophthalmology companies in California
#1
Science 🦄Series C · Alameda, California · founded 2021 · 76 employees$360Mraised▾
Science 🦄
Series C · Alameda, California · founded 2021 · 76 employees
Provider of online science magazine. They specialize in offering content in various topics such as science for patients,technologies and much more.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 13%Patents
top 20%Moat
top 24%Innovation
top 33%Growth
top 35%Market
top 38%Funding: Raised $360M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series C (Feb 2026)
Patents: 245 patents matched (strict assignee match) · 102 filings since 2022 vs 115 in 2017-21 · Latest publication 2026
Moat: IP moat: 245 patents · Unicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 14k LinkedIn followers — 6.7% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Senior Regulatory Specialist, Customer Service Engineer
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Feb 2026Series C$230M
- Mar 2025Series C$104M
- May 2024Series B$26M
Founders & team
Investors
Khosla Ventures, Lightspeed Venture Partners, Y Combinator, Quiet Capital, In-Q-Tel, Olive Capital
Tech stack
Apple Icloud MailAstroChakra UiDocusignEmotionGoogle Workspace
#2
Series B · Berkeley, California · founded 2021 · 10 employees$106Mraised▾
Series B · Berkeley, California · founded 2021 · 10 employees
Developer of therapeutics for degenerative retinal diseases. The lead candidate RAY-001 for Retinitis pigmentosa, RAY-002 for geography atrophy, and for other inherited retinal diseases.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 19%Growth
top 35%Tech
top 40%Moat
top 42%Talent
bottom 49%Global
bottom 39%Funding: Raised $106M across 6 rounds · 6 rounds over 4 yrs (1.5/yr) · Last round Series B (Apr 2026)
Growth: Fresh capital in last 24 mo
Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare, Fastly · Devops: Nginx, Varnish
Audience (LinkedIn): 8k LinkedIn followers — 3.7% of this cohort's audience
Funding rounds
- Apr 2026Series B$125M
- Apr 2025Grant (prize money)$8M
- Nov 2023Grant (prize money)$4M
- May 2023Series A$100M
Founders & team
Investors
4Bio Capital, Novo Holdings, Deerfield, MRLV, Platanus, Norwest
Tech stack
CloudflareCloudflare Bot ManagementComplianzCore-JsElementorGenesis Blocks
#3
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#4
Late Stage · Palo Alto, California · founded 2024$50Mraised▾
Late Stage · Palo Alto, California · founded 2024
Developer of therapeutics for retinal disorders. It offers a lead product, TH103 which is a fully humanized, recombinant fusion protein designed for intravitreal delivery as anti-VEGF agent for the treatment of neovascular age-related macular degeneration.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers — 2.7% of this cohort's audience
Funding rounds
- Dec 2025Post IPO$50M
Founders & team
Investors
ADAR1, Coastlands Capital, RTW Investments, Samsara BioCapital, Woodline Partners, Invus
#5
Series C · Redwood City, California · founded 2024$85.3Mraised▾
Series C · Redwood City, California · founded 2024
Developer of ophthalmology therapeutics for diseases like AMD, DME, RVO, and GA. It focuses on creating long-acting and effective delivery methods for clinically validated and emerging medicines used in treating major causes of blindness. With TransCon technology for ophthalmology, it aims to develop transformational therapies for eye diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Hiring: 5 hiring posts in 12 mo (public) · momentum -3 · hiring: Senior Research Associate / Associate Scientist, Associate Scientist / Scientist
Funding rounds
- Oct 2025Series C$25M
- Jan 2024Series C$60.3M
Founders & team
Tech stack
Apple Icloud MailCloudflareGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
#6
Series A · San Diego, California · founded 2014 · 10 employees$73.2Mraised▾
Series A · San Diego, California · founded 2014 · 10 employees
Developer protein engineering drugs to treat corneal endothelial diseases. The company's Lead candidate TTHX1114 is an engineered form of naturally-occurring Fibroblast Growth Factor -1 (FGF-1) that is designed to protect corneal endothelial cells and as well as restore vision loss due to corneal endothelial cell dystrophy by stimulating corneal endothelial cell proliferation and migration. Also, it develops another drug candidate an eye drop formulation of TTHX1114 for the treatment of ulcerative conditions.
Funding rounds
- Apr 2025Series A$4.6M
- Mar 2022Series A$12M
- Dec 2021Series A$28M
- Jul 2019Series A$28M
Founders & team
Investors
Hatteras Venture Partners, Bios Partners, Aju IB Investment, Correlation Ventures, InFocus Capital Partners, Exsight Ventures
#7
Series B · Redwood City, California · founded 2015 · 40 employees$130.4Mraised▾
Series B · Redwood City, California · founded 2015 · 40 employees
Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases. The company uses hydroxyl dendrimer technology to selectively target inflamed tissue, and its pipeline highlights migaldendranib (MGB) as a key candidate for ophthalmology, neurology, and inflammatory diseases.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 23%Moat
top 36%Talent
top 38%Market
bottom 41%Global
bottom 37%News
bottom 22%Funding: Raised $130M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) · Last round Series B (Jan 2025)
Moat: Editorial + unicorn rating 7/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Jan 2025Series B$50M
- Apr 2022Series B$69M
- Apr 2021Series A$60.2M
- May 2019Seed$250K
Founders & team
Investors
Huadong Medicine, Plum Alley Investments, Tribe Capital, Natural Capital Investment Fund, Natural Capital, Helios Capital
#8
Series B · Burlingame, California · founded 2019$15Mraised▾
Series B · Burlingame, California · founded 2019
Developer of therapeutics for autoimmunity and ophthalmological conditions. The company utilizes proprietary pathways and tailored formulations for precise delivery to relevant tissues. The company's product line include ILYX-002 for ocular complications of autoimmune diseases and ILYX-004 for retinal indications.
Funding rounds
- Dec 2025Series B$15M
Founders & team
Investors
Frazier Life Sciences, GC&H Investments
#9
Series D · San Francisco, California · founded 2012$200Mraised▾
Series D · San Francisco, California · founded 2012
Developer of small molecule therapies for neurological, cardiometabolic, and ophthalmic diseases. The company advances a pipeline of wholly owned, highly CNS-penetrant and peripherally-restricted small molecules. It focuses on resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company's expertise lies in optimizing molecular delivery properties, enabling the parallel development of CNS-penetrant and peripherally-restricted small molecules to maximize patient impact across a broad array of diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 8k LinkedIn followers — 3.6% of this cohort's audience
Hiring: 4 hiring posts in 12 mo (public) · momentum +4 · hiring: DMPK Scientist, medicinal chemist
Funding rounds
- Jan 2025Series D$200M
Founders & team
Investors
Arch Venture Partners, F-Prime Capital, Mubadala Capital, Eight Roads Ventures
#10
Series B · San Carlos, California · founded 2019 · 30 employees$18Mraised▾
Series B · San Carlos, California · founded 2019 · 30 employees
Developer of therapeutics for the treatment of age-related eye diseases. The company’s integrated platform includes machine learning, computational biology, drug discovery, and diagnostic development to develop treatments for age-related progressive diseases. The company has drugs for Age-related macular degeneration (AMD) and Glaucoma.
Funding rounds
- Sep 2025Series B$8.9M
- Mar 2025Series B$93M
- May 2022Series A$18M
Founders & team
Investors
Innovation Endeavors, Catalio Capital Management, Lifeforce Capital, Casdin Capital, Clover Health, Industry Ventures
#11
Series B · Del Mar, California · founded 2014$51.5Mraised▾
Series B · Del Mar, California · founded 2014
Sydnexis has developed a proprietary formulation for treating myopia. The patented eye drop formulation SYD-101 is developed to reduce the myopia progression which is associated with numerous serious ophthalmic co-morbidities in children.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Apr 2025Series B$20M
- Apr 2024Series B$999.8K
- Aug 2021Series B$45M
- Oct 2017Series A$5.5M
Founders & team
Investors
Visionary Ventures, SC Master Fund, Bluestem Capital, RA Capital Management, Longitude Capital, Medicxi
Tech stack
AkismetComplianzCore-JsElementorFont AwesomeGodaddy
#12
Series B · San Francisco, California · founded 2018$68Mraised▾
Series B · San Francisco, California · founded 2018
Developer of therapeutics for multiple diseases. It offers gene therapies using ultracompact Cas proteins which modulate gene expression without cutting DNA. The company's platform leverages the power of CRISPR/Cas9 gene editing to target specific genes and achieve therapeutic outcomes. The pipeline includes EPI-321 for facioscapulohumeral muscular dystrophy, EPI-221, EPI-224 for genetic disorder, EPI 114 and EPI 111 for petinas pigmentosa.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 23%Talent
top 38%Moat
top 42%Tech
bottom 43%Global
bottom 37%Market
bottom 32%Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Mar 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Mar 2025Series B$68M
Founders & team
Investors
Ally Bridge Group, Solve FSHD, LDV Partners
Funding & investor landscape
$5.4Btotal disclosed funding
102companies funded
361disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Max Hodak
Founder & CEO · Science
Paul Bresge
Co-Founder & CEO · Ray Therapeutics
Shankar Ramaswamy
Co-Founder & CEO · Kriya Therapeutics
Roger Jeffs
Co-Founder · Kriya Therapeutics
Srinivas Akkaraju
Co-Founder & Director · Kalaris Therapeutics
Napoleone Ferrara
Co-Founder · Kalaris Therapeutics
Oliver Stauch
Chief Operating Officer · Eyconis
Emmett Cunningham
Co-Founder & Executive Chairman of the Board · Eyconis
Michael Blaber
Co-Founder · Trefoil Therapeutics
Ralph Bradshaw
Co-Founder · Trefoil Therapeutics
Kannan Rangaramanujam
Co-Founder & CTO · Ashvattha Therapeutics
Jeffrey Cleland
Co-Founder & CEO · Ashvattha Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 11,129,114 docs
Market landscape — 10 sub-themes by coverage
Share of Ophthalmology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN CALIFORNIA · Health & Bio
How research on Medical Devices in California is moving
A read on the academic research around Medical Devices in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 110 papers.
UC San Francisco, Berkeley, and USC lead California's medical-device research, focusing predominantly on soft robotics and surgical simulation with a cautiously optimistic tone amid balanced breakthrough-concern findings.
110 papers · stance +0.32 · 29% breakthrough · 35% concern
top institutions
- University of California, San Francisco20
- University of California, Berkeley14
- University of Southern California13
- University of California San Diego12
- University of California, Los Angeles10
leading researchers
Joseph S. Ross · Sanket S. Dhruva · Florian Richter · Michael C. Yip · Rita F. Redberg · Jacob Rosén
prism intelligence · tone & topics
85% positive · 13% critical tone
HealthcareHealthBusinessMedical TechnologyRoboticsEducation
▲
Breakthroughs29 · 26%
▼ 30%→18% share
▼0.6× share momentum5 median citations41% since 2021mostly methods-led
Surgical robot breakthroughs cooling — field-share dropped 30%→18% despite Robot (15) and Surgical robot (11) paper counts.
rising sub-themes (early→recent)
- Robot15
- Surgical robot11
- Robotics6
- Computer vision6
- Biomedical engineering3
Landmark Degradation and antibacterial properties of magnesium alloys in artificial urine for potential resorbable ureteral stent · 153 cites
◆
Advancements35 · 32%
▲ 22%→35% share
▲1.6× share momentum2 median citations66% since 2021mostly methods-led
Surgical robotics advancements intensifying — field-share surged 22%→35% with Teleoperation newly emerging at 3 papers.
rising sub-themes (early→recent)
- Robot2→4
- Surgical robot3→5
- Biomedical engineering1→3
Newly emergingTeleoperation 0→3 · MEDLINE 0→3
Landmark Subdermal Flexible Solar Cell Arrays for Powering Medical Electronic Implants · 142 cites
▼
Concerns35 · 32%
▼ 48%→32% share
▼0.7× share momentum3 median citations60% since 2021mostly position pieces
Regulatory scrutiny rising sharply — Food and Drug Administration concern papers jumped 1→6, with Adverse effect newly flagged.
rising sub-themes (early→recent)
- Food and drug administration1→6
- Patient safety1→3
Newly emergingAdverse effect 0→3
Landmark Many-body–localized discrete time crystal with a programmable spin-based quantum simulator · 186 cites
Common questions
How many Ophthalmology companies are there in California, United States?
Radar tracks 170 indexable Ophthalmology companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Ophthalmology companies in California, United States?
The Ophthalmology companies in California, United States on this list have raised a combined $5.4B in disclosed equity funding across 102 funded companies.
Which is the highest-funded Ophthalmology company in California, United States?
Kriya Therapeutics is the highest-funded Ophthalmology company in California, United States, with $617.6M in disclosed equity funding.
How many Ophthalmology companies in California, United States are funded?
102 of the 170 Ophthalmology companies in California, United States on this list have disclosed at least one equity funding round.
How many Ophthalmology unicorns are there in California, United States?
1 Ophthalmology company in California, United States on this list is valued at $1B or more.
Who are the top investors in California, United States Ophthalmology companies?
The most active investors in California, United States Ophthalmology companies on this list include Versant Ventures, HHS, Exsight Ventures, Visionary Ventures, Catalio Capital Management.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.